Renal Insufficiency, Chronic Clinical Trial
Official title:
The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Patients
The aim of this study is to assess the impact of "adapted" Automated Peritoneal Dialysis(APD) sequentially prescribed shorter and longer dwell exchanges with smaller and larger fill volumes in comparison with "conventional APD" prescribed a standard continuous cycling peritoneal dialysis on the efficacy of dialysis.
It is well known that the efficiency of peritoneal dialysis (PD) varies with the duration of
the dwell and the prescribed fill volume. Short dwell ensures adequate UF because the
osmotic gradient is maintained while prolonged dwell allows for more solute clearance
because the dialysate-to-plasma ratio (D/P) for uremic toxins such as creatinine and
phosphate enhances. In terms of intraperitoneal fill volume, large fill volume improves the
removal of uremic toxins for two reasons: a larger volume can be drained and therefore the
clearance achieved is greater, and the peritoneal surface area available for the exchange is
increased. Conversely, small fill volume promotes the process of UF because of the
potentially low intraperitoneal pressure (IPP). Overall, choosing the optimal dwell time and
exchange volume should promote UF and increase the removal of uremic toxins—urea in
particular—to the dialysate.
Thus, this study proposes a new way of giving PD, using a modified version of conventional
prescription which firstly uses 2 cycles of short dwell time with a small fill volume to
promote UF and subsequently uses 2 cycles of longer dwell time and a larger fill volume to
promote removal of uremic toxins from the blood.
Although it was already evaluated the efficiency of this modified prescription by Fischbach
et al, the prescription currently prescribed in most Korean hospitals shows some differences
in dwell time, fill volume and exchange cycling. The aim of this study is to assess the
clinical effect of "Korean Adapted APD" (KAPD-A) compared to "Korean Conventional APD"
(KAPD-C).
This is a multicenter, randomized, open-label, parallel controlled study. Patients who meet
inclusion criteria will be randomized into each group at the ratio of 1:1. For incident
patients, after being stable on APD and peritonitis-free at least 4 weeks, which is called
as "run-in period", group 1 will start with 8 weeks of KAPD-C treatment and then cross over
to 8 weeks of treatment with KAPD-A while group 2 will be performed on the contrary from
KAPD-A to KAPD-C treatment.
Each patient will receive the same total amount of dialysate (8000 mL), given over the same
8-hour duration. First at the inclusion visit called "as baseline", and then visits will
take place every 4 weeks for a total of 16 weeks.
;
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05056727 -
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
|
Phase 3 | |
| Withdrawn |
NCT01655186 -
A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus
|
Phase 2 | |
| Completed |
NCT03481686 -
Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections
|
N/A | |
| Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
| Enrolling by invitation |
NCT02237534 -
Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia
|
Phase 4 | |
| Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
| Terminated |
NCT01533545 -
Effect of Epinephrine on Systemic Absorption of Mepivacaine in Uremic Patients
|
N/A | |
| Completed |
NCT03280615 -
Omega 3 Fatty Acids in Patients With Chronic Renal Disease
|
Phase 3 | |
| Completed |
NCT04498156 -
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
|
||
| Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
| Recruiting |
NCT06366529 -
Explore New Magnetic Resonance Technology in Assessment of Renal Dysfunction
|
||
| Active, not recruiting |
NCT04876963 -
HOLT-ED: Holter-monitoring in End-stage Renal Disease
|
||
| Completed |
NCT03836508 -
Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis
|
N/A | |
| Completed |
NCT03250715 -
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
|
N/A | |
| Completed |
NCT03577249 -
Biological Effects of Citrate-buffered Solutions on Dialysis Efficiency and Systemic Inflammation
|
Phase 2/Phase 3 | |
| Completed |
NCT01975818 -
Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
|
Phase 2 | |
| Active, not recruiting |
NCT05766644 -
App-based Education Program for CKD
|
N/A | |
| Active, not recruiting |
NCT02791880 -
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
|
||
| Recruiting |
NCT02947750 -
Neurovascular Transduction During Exercise in Chronic Kidney Disease
|
Phase 2 | |
| Terminated |
NCT02286258 -
Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
|
Phase 1/Phase 2 |